Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab
Failure to induce clinical remission at end of study · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in failure to induce clinical remission at week 10 compared with placebo and two infusions of infliximab (moderate certainty).
1 finding from 1 review
- RR 0.9 [0.65, 1.24]1 study · 79 participantsModerate